Benzinga | Oct 14, 2021 07:11AM EDT

CytoSorbents Announces First Patient Enrolled In U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR Antithrombotic Removal System To Remove Ticagrelor During Cardiothoracic Surgery

CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that the first patient has been enrolled in the Safe and Timely Antithrombotic Removal-Ticagrelor (STAR--T) double-blind, randomized, controlled clinical trial designed to support FDA marketing approval of the DrugSorb-ATR(tm) Antithrombotic Removal System for intraoperative removal of ticagrelor during cardiothoracic surgery. The STAR-T trial received full FDA IDE Approval in July 2021, and is being performed under the auspices of FDA Breakthrough Designation granted in April 2020. The STAR-T trial is expected to enroll up to 120 patients across 20 sites and be completed by 2022. The first patient was enrolled by Dr. Bradley S. Taylor, Chief of the Division of Cardiac Surgery and Director of Coronary Revascularization and site Principal Investigator at the University of Maryland Medical Center.